ROP Stock Analysis: Roche Holding | SW
Drug Manufacturers - General | SW, Switzerland | Market Cap: 280.382m CHF | 12M Return: 42.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 275M
Rev. Trend: 59.3%
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, operating across two core segments: pharmaceuticals and diagnostics. The company markets therapies across a wide range of therapeutic areas, including oncology, haematology, neurology, immunology, infectious diseases, ophthalmology, and respiratory disorders, alongside in vitro diagnostic tests, instruments, and digital health solutions used to detect conditions such as cancer, diabetes, Covid-19, and hepatitis. Roche is notable within the healthcare sector for its integrated pharma-diagnostics business model, which is relatively uncommon among large pharmaceutical peers and supports a broader personalised healthcare approach. The company is listed on the Swiss exchange under the ticker ROP and is classified within the Health Care sector (Pharmaceuticals sub-industry), with a mega-cap market capitalisation.
- New ophthalmology and oncology launches offset legacy biosimilar erosion
- Diagnostics revenue normalizes after COVID-19 testing windfall fades
- Carmot acquisition expands pipeline into obesity and GLP-1 market
| Net Income: 12.3b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 1.75 > 1.0 |
| NWC/Revenue: 10.81% < 20% (prev 12.98%; Δ -2.16% < -1%) |
| CFO/TA 0.19 > 3% & CFO 18.4b > Net Income 12.3b |
| Net Debt (23.6b) to EBITDA (22.8b): 1.03 < 3 |
| Current Ratio: 1.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (809.3m) vs 12m ago 0.65% < -2% |
| Gross Margin: 73.32% > 18% (prev 73.13%; Δ 0.19% > 0.5%) |
| Asset Turnover: 63.16% > 50% (prev 66.04%; Δ -2.88% > 0%) |
| Interest Coverage Ratio: 14.07 > 6 (EBIT TTM 19.5b / Interest Expense TTM 1.38b) |
| A: 0.07 (Total Current Assets 35.4b - Total Current Liabilities 28.8b) / Total Assets 98.2b |
| B: 0.50 (Retained Earnings 48.8b / Total Assets 98.2b) |
| C: 0.20 (EBIT TTM 19.5b / Avg Total Assets 96.5b) |
| D: 0.53 (Book Value of Equity 32.7b / Total Liabilities 61.5b) |
| Altman-Z'' = 3.97 = AA |
| DSRI: 1.11 (Receivables 13.3b/12.4b, Revenue 60.9b/62.6b) |
| GMI: 1.00 (GM 73.13% / 73.32%) |
| AQI: 1.05 (AQ_t 0.40 / AQ_t-1 0.38) |
| SGI: 0.97 (Revenue 60.9b / 62.6b) |
| TATA: -0.06 (NI 12.3b - CFO 18.4b) / TA 98.2b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of July 28, 2026, the stock is trading at CHF 360.10 with a total of 846,206 shares traded. Over the past week, the price has changed by +8.56%, over one month by +6.29%, over three months by +12.11% and over the past year by +42.41%.
Current recommended Stop Loss: 349.40 (which is 3% or 1.4 ATR below the current price).
Roche Holding has no consensus analysts rating.
P/E Trailing = 20.8472
P/E Forward = 16.3132
P/S = 4.4268
P/B = 7.8239
P/EG = 1.4556
Revenue TTM = 60.9b CHF
EBIT TTM = 19.5b CHF
EBITDA TTM = 22.8b CHF
Long Term Debt = 27.4b CHF (from longTermDebt, last fiscal year)
Short Term Debt = 6.58b CHF (from shortTermDebt, last quarter)
Debt = 33.4b CHF (from shortLongTermDebtTotal, last quarter) + Leases 1.55b
Net Debt = 23.6b CHF (calculated: Debt 33.4b - CCE 9.73b)
Enterprise Value = 304b CHF (280b + Debt 33.4b - CCE 9.73b)
Interest Coverage Ratio = 14.07 (Ebit TTM 19.5b / Interest Expense TTM 1.38b)
EV/FCF = 20.59x (Enterprise Value 304b / FCF TTM 14.8b)
FCF Yield = 4.86% (FCF TTM 14.8b / Enterprise Value 304b)
FCF Margin = 24.23% (FCF TTM 14.8b / Revenue TTM 60.9b)
Net Margin = 20.25% (Net Income TTM 12.3b / Revenue TTM 60.9b)
Gross Margin = 73.32% ((Revenue TTM 60.9b - Cost of Revenue TTM 16.3b) / Revenue TTM)
Gross Margin QoQ = 73.72% (prev 72.93%)
Tobins Q-Ratio = 3.10 (Enterprise Value 304b / Total Assets 98.2b)
Interest Expense / Debt = 4.15% (Interest Expense 1.38b / Debt 33.4b)
Taxrate = 18.74% (3.07b / 16.4b)
NOPAT = 15.8b (EBIT 19.5b * (1 - 18.74%))
Current Ratio = 1.23 (Total Current Assets 35.4b / Total Current Liabilities 28.8b)
Debt / Equity = 1.02 (Debt 33.4b / totalStockholderEquity, last quarter 32.7b)
Debt / EBITDA = 1.03 (Net Debt 23.6b / EBITDA 22.8b)
Debt / FCF = 1.60 (Net Debt 23.6b / FCF TTM 14.8b)
Total Stockholder Equity = 31.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.79% (Net Income 12.3b / Total Assets 98.2b)
RoE = 38.89% (Net Income TTM 12.3b / Total Stockholder Equity 31.7b)
RoCE = 32.88% (EBIT 19.5b / Capital Employed (Equity 31.7b + L.T.Debt 27.4b))
RoIC = 21.69% (NOPAT 15.8b / Invested Capital 72.9b)
WACC = 5.75% (E(280b)/V(314b) * Re(6.03%) + D(33.4b)/V(314b) * Rd(4.15%) * (1-Tc(0.19)))
Discount Rate = 6.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -50.34 | Cagr: -2.54%
[DCF] Terminal Value 77.97% ; FCFF base≈13.9b ; Y1≈15.9b ; Y5≈23.4b
[DCF] Fair Price = 476.9 (EV 353b - Net Debt 23.6b = Equity 329b / Shares 690.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
Revenue Correlation: 59.26 | Revenue CAGR: 1.61% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=20.14 | Chg30d=-0.27% | Revisions=-25% | GrowthEPS=+3.5% | GrowthRev=+1.8%
EPS next Year (2027-12-31): EPS=21.70 | Chg30d=-0.38% | Revisions=-25% | GrowthEPS=+7.8% | GrowthRev=+4.3%
[Analyst] Revisions Ratio: -40% (up=0, down=2)